Abstracts tagged "pain and pain management"

Abstract Number: 2225 • 2017 ACR/ARHP Annual Meeting
Cntx-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): An Open-Label, Ascending-Dose Study
Peter Hanson¹, Ira Gottlieb², Margaret Kelly³, James Campbell¹, Robert Allen⁴ and Randall Stevens¹, ¹Centrexion Therapeutics, Boston, MA, ²Chesapeake Research Group, Pasadena, MD, ³Edirutop, Christiansburg, VA, ⁴Allen Medical LLC, Malvern, PA
Background/Purpose: Morton’s neuroma (MN) is a painful condition of the third intermetatarsal space caused by distal common digital nerve compression. CNTX-4975, a highly purified, synthetic…
Abstract Number: 2243 • 2014 ACR/ARHP Annual Meeting
Comparison Between Two Diclofenac Diethylamine Gel Formulations, 1.16% Vs 2.32%: Is It Only Increasing the Strength of the Active Ingredient Enough?
Giuseppa Quartarone¹ and Nathalie Hasler-Nguyen², ¹Medical Affairs, Novartis CH R&D OU Italy Greece, Milan, Italy, ²Pre-Cinical Development, Novartis CH Global R&D, Nyon, Switzerland
Background/Purpose Topically applied non-steroidal anti-inflammatory drugs (NSAIDs) can produce clinically effective drug concentrations at a peripheral site, but with low systemic concentrations and thus a…
Abstract Number: 250 • 2014 ACR/ARHP Annual Meeting
Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment
Paul M. Peloso¹, Ted R. Mikuls², Brian W. Coburn³, H. Ralph Schumacher Jr.⁴, Davis F. Gates¹, Zoran Popmihajlov¹, Walter L. Straus¹ and R. Andrew Moore⁵, ¹Merck & Co., Inc., Whitehouse Station, NJ, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Oxford, Nuffield Division of Anaesthetics, Oxford, England
Background/Purpose This post-hoc analysis from a randomized trial1in acute gout asked whether early pain responses predict subsequent pain and investigator global responses. Methods Patient assessment…
Abstract Number: 249 • 2014 ACR/ARHP Annual Meeting
A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes
Vibeke Strand¹, Allan Gibofsky², Marc Hochberg³, Roy Altman⁴, Byron Cryer⁵, Alan Kivitz⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹Stanford University, Palo Alto, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³University of Maryland School of Medicine, College Park, MD, ⁴University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA
Background/Purpose: Diclofenac is used for the treatment of osteoarthritis (OA), but, like other NSAIDs, it is associated with serious dose-related adverse events. The FDA has…
Abstract Number: 1868 • 2012 ACR/ARHP Annual Meeting
Clinical Outcome in Fibromyalgia Patients Treated with Milnacipran Is Largely Independent of Symptom Duration
Philip J. Mease¹, Robert M. Bennett², Robert H. Palmer³ and Yong Wang⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine & Nursing, Oregon Health & Science University, Portland, OR, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: Patients with fibromyalgia (FM) usually experience pain, fatigue, and other debilitating symptoms for years. In clinical studies ranging from 3 months to >3 years,…
Abstract Number: 1857 • 2012 ACR/ARHP Annual Meeting
Identifying Core Symptom Domains in the Fibromyalgia Impact Questionnaire: Principal Component Analysis of Data From Milnacipran Clinical Studies
Philip J. Mease¹, Robert M. Bennett², Robert H. Palmer³ and Yong Wang⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: The Fibromyalgia Impact Questionnaire (FIQ) is a multidimensional instrument that encompasses many of the core domains recommended by OMERACT for evaluation in fibromyalgia (FM)…
Abstract Number: 963 • 2012 ACR/ARHP Annual Meeting
Efficacy of Long-Term Milnacipran Treatment in Patients Meeting Different Thresholds of Clinically Relevant Pain Relief: Subgroup Analysis of a Double-Blind, Placebo-Controlled Discontinuation Study
Daniel J. Clauw¹, Philip J. Mease², Robert H. Palmer³, Joel M. Trugman⁴ and Yimin Ma⁴, ¹Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: Patients with fibromyalgia (FM) who received up to 3.25 years of milnacipran (MLN) in a flexible-dose (≤200 mg/d) open-label (OL) study were eligible to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].